Intermittent Chemotherapy and Erlotinib for Nonsmokers or Light Smokers with Advanced Adenocarcinoma of the Lung: A Phase II Clinical Trial

Background. Intermittent application of chemotherapy and tyrosine kinase inhibitors may avoid antagonism between the two classes of drugs. This hypothesis was tested in a Phase II clinical trial. Patients and Methods. Eligible patients were nonsmokers or light smokers, chemo-naïve, with metastatic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zwitter, Matjaz, Rajer, Mirjana, Kovac, Viljem, Kern, Izidor, Vrankar, Martina, Smrdel, Uros
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085288/
https://www.ncbi.nlm.nih.gov/pubmed/21541241
http://dx.doi.org/10.1155/2011/185646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085288/
https://www.ncbi.nlm.nih.gov/pubmed/21541241
http://dx.doi.org/10.1155/2011/185646

Ejemplares similares